Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA520358
Max Phase: Preclinical
Molecular Formula: C22H22N4O
Molecular Weight: 358.45
Molecule Type: Small molecule
Associated Items:
ID: ALA520358
Max Phase: Preclinical
Molecular Formula: C22H22N4O
Molecular Weight: 358.45
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: COc1cc(-c2ccccc2)cc(C(C)C#Cc2c(C)nc(N)nc2N)c1
Standard InChI: InChI=1S/C22H22N4O/c1-14(9-10-20-15(2)25-22(24)26-21(20)23)17-11-18(13-19(12-17)27-3)16-7-5-4-6-8-16/h4-8,11-14H,1-3H3,(H4,23,24,25,26)
Standard InChI Key: JPENSYBRTSIYGO-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 358.45 | Molecular Weight (Monoisotopic): 358.1794 | AlogP: 3.78 | #Rotatable Bonds: 3 |
Polar Surface Area: 87.05 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 7.29 | CX LogP: 4.14 | CX LogD: 3.89 |
Aromatic Rings: 3 | Heavy Atoms: 27 | QED Weighted: 0.70 | Np Likeness Score: -0.49 |
1. Bolstad DB, Bolstad ES, Frey KM, Wright DL, Anderson AC.. (2008) Structure-based approach to the development of potent and selective inhibitors of dihydrofolate reductase from cryptosporidium., 51 (21): [PMID:18834108] [10.1021/jm8009124] |
2. Paulsen JL, Liu J, Bolstad DB, Smith AE, Priestley ND, Wright DL, Anderson AC.. (2009) In vitro biological activity and structural analysis of 2,4-diamino-5-(2'-arylpropargyl)pyrimidine inhibitors of Candida albicans., 17 (14): [PMID:19560363] [10.1016/j.bmc.2009.06.021] |
3. Beierlein JM, Karri NG, Anderson AC.. (2010) Targeted mutations of Bacillus anthracis dihydrofolate reductase condense complex structure−activity relationships., 53 (20): [PMID:20882962] [10.1021/jm100727t] |
4. Zhou W, Scocchera EW, Wright DL, Anderson AC. (2013) Antifolates as effective antimicrobial agents: new generations of trimethoprim analogs, 4 (6): [10.1039/C3MD00104K] |
5. G-Dayanandan N, Paulsen JL, Viswanathan K, Keshipeddy S, Lombardo MN, Zhou W, Lamb KM, Sochia AE, Alverson JB, Priestley ND, Wright DL, Anderson AC.. (2014) Propargyl-linked antifolates are dual inhibitors of Candida albicans and Candida glabrata., 57 (6): [PMID:24568657] [10.1021/jm401916j] |
6. Zhou W, Viswanathan K, Hill D, Anderson AC, Wright DL.. (2012) Acetylenic linkers in lead compounds: a study of the stability of the propargyl-linked antifolates., 40 (10): [PMID:22815313] [10.1124/dmd.112.046870] |
7. (2014) Heterocyclic analogs of propargyl-linked inhibitors of dihydrofolate reductase, |
Source(2):